Will GDUFA III Curtail Priority Assessments?
Executive Summary
US FDA's expedited pathway for generics seems to provide more benefits for amendments than for original ANDAs.
You may also be interested in...
FDA And Industry Set Out GDUFA III Priorities
Both first-cycle approvals and priority assessment improvements have been the subject of questions and criticism as the FDA and industry attempt to boost generic competition.
GDUFA III: First-Cycle Approval, Priority Assessment Improvements Are Early Priorities
Both issues have been the subject of questions and criticism as the FDA and industry attempt to boost generic competition.
GDUFA III: How Much Of A Fee Increase Can Industry Stomach?
Amid questions about generic industry market dynamics, the user fee renewal could focus on limiting increases in US FDA collections.